Home About Us Services Markets Resarch Online Trading Back Office Contact Us Download
Your are on :   Markets   |  Corporate Action   |  BSE Announcements As on : 20-Oct-2020
Batliboi
Batliboi will hold a meeting of the Board of Directors of the Company on 6 November 2020.
Oriental Aromat.
Oriental Aromatics announced that its subsidiary, Oriental Aromatics & Sons has received allotment letter for land at Mahad Five Star Industrial Area from Maharashtra Industrial Development Corporation (MIDC) for the purpose of setting up of its plant/ manufacturing unit.
Century Enka
Century Enka will hold a meeting of the Board of Directors of the Company on 28 October 2020.
Cipla
Cipla announced that it has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib. This launch marks yet another milestone in Cipla's decade-long commitment to treat IPF, a rare lung disease that impacts ten in one lakh people.

Cipla's journey in IPF began in 2010 with the introduction of Pirfenex, the world's first generic Pirfenidone and the first ever approved drug for IPF in India. Further to this, Cipla reduced the cost of its IPF therapy by 40% in 2013 to provide patient-access to this critical treatment. In line with its endeavour of enabling effective and affordable management of IPF, Cipla's Nintib is priced at Rs. 69 (100 mg) and Rs. 85 (150 mg) per capsule.

IPF is a chronic progressive form of lung disease with an average survival rate of three to five years if left untreated. It is characterized by scarring in the lungs, wherein the lung tissue becomes stiff and thick. This interferes with a person's ability to breathe and reduces oxygen supply to the blood, resulting in shortness of breath. Over the past ten years, Cipla has played a pivotal role in creating awareness on the diagnosis and treatment of IPF amongst the medical fraternity.

EIH
The Rights Issue Committee of EIH at its meeting held on 20 October 2020 has approved the allotment of 5,37,94,768 Rights Equity Shares at a price of Rs 65 per Rights Equity Share (including premium of Rs 63).

Accordingly, pursuant to the aforesaid Allotment, the paid-up equity share capital of the Company has increased to Rs 1,25,07,28,364.

Prev   |  Next 
Home About Us Product Disclaimer Markets Research Privacy Policy Careers Contact Us Feedback Scores
"Investor Grievance" Mail your Grievance to info@lalkar.in Important Links:   SEBI   |   NSE   |   BSE   |   MCX-SX   |   MCX   |   NCDEX   |   NSDL   |   CDSL   |   FMC
SEBI REGISTRATION NOS - NSE: INB230991136  |  NSE F&O: INF230991136  |  NSE CDS: INE230991136  |  BSE: INB010991133  |  BSE F&O: INF010991133  |  MCX-SX Cash INB 260991139 | MCX-SX F&O INF 260991139 | MCX-SX CDs INE 260991136 | CDSL: IN-DP-CDSL-383-2006
AMFI NO : ARN- 19226  |  LALKAR COMMODITIES PVT. LTD.: MCX: 10685 FMC: MCX/TCM/CORP/0655 | NSEL: 11300 | NCDEX: 1130 FMC No : NCDEX/TCM/CORP/1106
2010 © Lalkar Group. All rights reserved Designed, developed & powered by CMOTS Infotech(ISO 9001:2015 certified)